Quince therapeutics receives u.s. fda fast track designation for erydex system

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the u.s. food and drug administration (fda) has granted fast track designation for its erydex system for the treatment of patients with ataxia-telangiectasia (a-t). erydex is comprised of dexamethasone sodium phosphate (ds.
QNCX Ratings Summary
QNCX Quant Ranking